Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai, Dundee Univ. Ink Oncology Drug Discovery Deal
July 9, 2019
- Vortioxetine Hits Japan PIII Target for MDD: Takeda/Lundbeck
July 9, 2019
- Maviret, Lyrica Sell Big; Avastin Presumed No. 1 in FY2018 Drug Ranking: Tally
July 8, 2019
- Keytruda Retains Top Slot in Drug Sales Ranking in June: Encise Snapshot
July 8, 2019
- Japan Ethical Drug Sales Down 3.8% in May Due to Holidays: Crecon
July 8, 2019
- CureApp’s Smoking Cessation App under Review as Medical Device; Reimbursement Price Will Be Key: President
July 8, 2019
- Genomic Profiling Tests Need More of Private Insurer Involvement: Prof.
July 5, 2019
- Allogeneic Cell Therapies Well Suited to Pharma's Biz Model, Education of Data Scientists Important: Astellas Chairman
July 4, 2019
- Claw-Back Clause Thwarted, but Majority of Takeda Shareholders Voted in Favor
July 4, 2019
- Avastin Most Prescribed Drug at Acute Hospitals in 2018
July 3, 2019
- Sumitomo Dainippon’s Napabucasin Flops in Pancreatic Cancer Trial
July 3, 2019
- Takeda Completes Divestment of Dry Eye Drug Xiidra to Novartis
July 3, 2019
- Fujifilm Launches New US Company to Develop Allogeneic iPS Cell-Derived Cancer Immunotherapies
July 3, 2019
- Fujifilm to Invest 3 Billion Yen in New Plant in Netherlands to Boost Cell Culture Media Production
July 3, 2019
- Taisho Completes US$1.5 Billion Acquisition of Bristol-Myers’ OTC Unit
July 3, 2019
- Mikitani Resolved to Grow Rakuten Medical into Global Biotech
July 2, 2019
- CheckMate-227 Lung Cancer Data Will Make or Break Opdivo’s Fate: Analyst
July 2, 2019
- JACE Now Eligible for Health Coverage for Epidermolysis Bullosa
July 2, 2019
- ASKA, RaQualia Team Up for Drug Discovery Research, Employing Ion Channel Technology
July 2, 2019
- Takeda’s Medical Unit Revving Up “Patient First Program” as It Looks beyond the Pill
July 1, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…